Efectividad de las vacunas e intensidad de la respuesta serológica asociada a la Covid – 19

Keyla Jacqueline  Cabezas Tunja; Katherine Maricela  Santistevan León; José Clímaco  Cañarte Vélez

Authors

Keyla Jacqueline Cabezas Tunja
Katherine Maricela Santistevan León
José Clímaco Cañarte Vélez

Keywords:

vaccine; COVID – 19; effectiveness; immunogenicity.

Abstract

In response to the pandemic, global initiatives aimed at developing multiple vaccines to protect against COVID - 19, for this reason this research seeks to study the effectiveness of vaccines and the intensity of the serological response associated with COVID - 19; This scientific-bibliographical research work allows knowing the investigations that have been carried out in the course of the disease as well as in the applications of the vaccines that have been approved by the WHO. Vaccines against COVID-19 that are currently in application have shown promising immunogenicity with a variable degree of efficacy against the development of moderate or severe disease, which indicates that the efficacy of the vaccines, especially the BNT162b2 and mRNA-1273 vaccines, present high standards in the analyzed studies that promise to be reliable for humanity.

Downloads

Download data is not yet available.

References

Beaumont, P. (08 de 11 de 2020). Covid-19 vaccine: who are countries prioritising for first doses? The Guardian. Recuperado el 18 de 09 de 2022, de https://www.theguardian.com/world/2020/nov/18/covid-19-vaccine-who-are-countries-prioritising-for-first-doses

Benotmane, I., Bruel, T., Planas, D., Fafi, S., Schwartz, O., & Caillard, S. (2021, 11 28). A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients. medRxiv. doi:https://doi.org/10.1101/2021.11.25.21266704

Caillard, S., Thaunat, O., Benotmane, I., Masset, C., & Blancho, G. (2022, 03). Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series. Annals of Internal Medicine. doi:https://doi.org/10.7326/L21-0598

Cardemil, C., M Dahl, R., James, L., Wannemuehler, K., Gary, H., Shah, M., . . . Quinlisk, P. (2017, 09 07). Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. The New England journal of Medicine, 377(10), 947 - 956. doi:10.1056/NEJMoa1703309

Craven, J. (24 de 06 de 2022). COVID-19 vaccine tracker. Recuperado el 19 de 09 de 2022, de Regulatory Focus: https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker

Crowcroft, N., & Klein, N. (19 de 11 de 2018). A framework for research on vaccine effectiveness. Vaccine, 36(48), 7286 - 7293. doi:10.1016/j.vaccine.2018.04.016

DIME. (2020). Sobre las vacunas en fase III para COVID-19. Boletín 26, Decisiones Informadas sobre Medicamentos . Recuperado el 19 de 09 de 2022, de http://pensamiento.unal.edu.co/fileadmin/recursos/focos/medicamentos/docs/ACTUALIZACION_DIME_COVID-Boletin__26.pdf

Folegatti, P., Ewer, K., Aley, P., Angus, B., Becker, S., Belij, S., . . . Green, C. (2020, 07 20). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet, 396(10249), 467 - 478. doi:https://doi.org/10.1016/S0140-6736(20)31604-4

Ivanova, P. (11 de 11 de 2020). Russia says its Sputnik V COVID-19 vaccine is 92% effective. REUTERS. Recuperado el 19 de 09 de 2022, de https://www.reuters.com/article/us-health-coronavirus-russia-vaccine/russia-says-its-sputnik-v-covid-19-vaccine-is-92-effective-idUSKBN27R0Z6

Jackson, L., Anderson, E., Rouphael, N., Roberts, P., Makhene, M., Coler, R., . . . Morabito, K. (2020, 11 12). An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. The New England Journal of Medicine, 1920 - 1931. doi:10.1056/NEJMoa2022483

Kamar, N., Abravanel, F., Marion, O., Romieu, R., Couat, C., Bello, A., & Izopet, J. (2021, 11 24). Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant. JAMA, 4(11). doi:10.1001/jamanetworkopen.2021.36030

Kanaan, M., & Farrington, P. (06 de 2002). Estimation of Waning Vaccine Efficacy. Journal of the American Statistical Association, 97(458), 389 - 397. Recuperado el 18 de 09 de 2022, de https://www.jstor.org/stable/3085652

Lipsitch, M., Goldstein, E., Ray, G. T., & Fireman, B. (2019, 11 27). Depletion-of-susceptibles bias in influenza vaccine waning studies: how to ensure robust results. Epidemiology and Infection, 147(306). doi:https://doi.org/10.1017/S0950268819001961

Logunov, D., Dolzhikova, I., Zubkova, O., Tukhvatulin, A., Shcheblyakov, D., Dzharullaeva, A., . . . Botikov, A. (2020, 09 26). Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet, 396(10255), 887 - 897. doi:https://doi.org/10.1016/S0140-6736(20)31866-3

MODERNA. (16 de 11 de 2020). Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study. BioSpace. Recuperado el 19 de 09 de 2022, de https://www.biospace.com/article/releases/moderna-s-covid-19-vaccine-candidate-meets-its-primary-efficacy-endpoint-in-the-first-interim-analysis-of-the-phase-3-cove-study/

O.P.S. (2021). Evaluación de la efectivad de las vacunas contra la COVID - 19. Organización Mundial de la Salud, Organización Panamericana de la Salud. Orientación Provicional. Recuperado el 18 de 09 de 2022, de https://iris.paho.org/bitstream/handle/10665.2/54270/OPSWFPLIMCOVID-19210028_spa.pdf?sequence=4

O'Hagan, J., Hernán, M., Walensky, R., & Lipsitch, M. (14 de 01 de 2012). Apparent declining efficacy in randomized trials: examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials. AIDS, 26(2), 123 - 126. doi:https://doi.org/10.1097/QAD.0b013e32834e1ce7

OPS. (1 de 02 de 2020). Alertas y actualizaciones epidemiológicas. Obtenido de Organizacón Panamericana de la Salud: https://www.paho.org/es/alertas-actualizaciones-epidemiologicas

Pfizer. (09 de 11 de 2020). Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study. Recuperado el 19 de 09 de 2022, de Pfizer: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against

Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., Stoop, J., . . . Van, P. (2020, 09 25). Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. MedRxiv. doi:https://doi.org/10.1101/2020.09.23.20199604

Schwartz, K., Crowcroft, N., Savage, R., Chen, C., Johnson, C., Marchand, A., . . . Kwong, J. (2021, 07 1). A Call for Caution in Use of Pertussis Vaccine Effectiveness Studies to Estimate Waning Immunity: A Canadian Immunization Research Network Study. Clinical Infestious Diases, 73(1), 83 - 90. doi:https://doi.org/10.1093/cid/ciaa518

Vélez, M., & Vélez-Marín, V. (2020). Síntesis Rápida: Vacunas para la COVID-19: evidencia sobre seguridad, inmunogenicidad y eficacia. Síntesis Rápida, Universidad de Antoquia, Facultad de Medicina, Antoquia. Recuperado el 19 de 09 de 2022, de https://docs.bvsalud.org/biblioref/2021/04/1151966/udea_uned_sintesisrapida_covid19_vacunas_eficacia_rapidlivings_44V6elI.pdf

W.H.O. (16 de 09 de 2022). COVID-19 vaccine tracker and landscape. Recuperado el 18 de 09 de 2022, de World Health Organitation: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

WHO. (17 de 09 de 2022). WHO Coronavirus (COVID-19) Dashboard. Recuperado el 18 de 09 de 2022, de World Health Organization: https://covid19.who.int/

Wu, S., Zhong, G., Zhang, J., Shuai, L., Wen, Z., Wang, B., . . . Chen, Y. (2020, 08 14). A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nature Communications, 11(4081). doi:https://doi.org/10.1038/s41467-020-17972-1

Zerbo, O., Bartlett, J., Goddard, K., Fireman, B., Lewis, E., & Klein, N. (2019, 07). Acellular Pertussis Vaccine Effectiveness Over Time. Pediatrics, 144(1). doi:10.1542/peds.2018-3466

Zhan, Y., Zeng, G., Li, C., Pan, H., Hu, Y., Kan, B., . . . Han, W. (2020, 08 10). Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial. medRxiv. doi:https://doi.org/10.1101/2020.07.31.20161216

Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., & Chu, K. (2021, 02 01). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet, 21(2), 181 - 192. doi:https://doi.org/10.1016/S1473-3099(20)30843-4

Zhu, F. C., Guan, X. H., Huang, J. Y., Li, Y. H., Jiang, T., Hou, L. H., . . . Wang, B. S. (2020, 08 15). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 396(10249), 479 - 488. doi:https://doi.org/10.1016/S0140-6736(20)31605-6

Zhu, F. C., Li, Y. H., Guan, X. H., Hou, L. H., Wang, W. J., Li, J. X., . . . Gou, J. B. (2020, 06 13). Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet, 395(10240), 1845 - 1854. doi:https://doi.org/10.1016/S0140-6736(20)31208-3